RNA editing is the next frontier in gene therapy—here’s what you need to know
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.
Facebook Comments
https://www.sarkaridoctor.com/wp-content/uploads/2022/01/logo@2xx.png00aajahttps://www.sarkaridoctor.com/wp-content/uploads/2022/01/logo@2xx.pngaaja2024-11-24 12:03:152024-11-24 12:03:15RNA editing is the next frontier in gene therapy—here’s what you need to know
